CY1119993T1 - Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης - Google Patents

Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης

Info

Publication number
CY1119993T1
CY1119993T1 CY20171101338T CY171101338T CY1119993T1 CY 1119993 T1 CY1119993 T1 CY 1119993T1 CY 20171101338 T CY20171101338 T CY 20171101338T CY 171101338 T CY171101338 T CY 171101338T CY 1119993 T1 CY1119993 T1 CY 1119993T1
Authority
CY
Cyprus
Prior art keywords
solid
surfactant
polymeric carrier
disconnectors
factors
Prior art date
Application number
CY20171101338T
Other languages
Greek (el)
English (en)
Inventor
Esther RÖSCH
Peter Hoelig
David J. Lindley
Yeshwant D. Sanzgiri
Ping Tong
Original Assignee
Abbvie Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119993(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Ireland Unlimited Company filed Critical Abbvie Ireland Unlimited Company
Publication of CY1119993T1 publication Critical patent/CY1119993T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20171101338T 2010-10-29 2017-12-20 Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης CY1119993T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40852710P 2010-10-29 2010-10-29
PCT/US2011/054959 WO2012121758A1 (en) 2010-10-29 2011-10-05 Melt-extruded solid dispersions containing an apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
CY1119993T1 true CY1119993T1 (el) 2018-12-12

Family

ID=44903438

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101338T CY1119993T1 (el) 2010-10-29 2017-12-20 Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης

Country Status (41)

Country Link
US (2) US20120108590A1 (enExample)
EP (3) EP4218731A3 (enExample)
JP (2) JP5902187B2 (enExample)
KR (2) KR101957137B1 (enExample)
CN (2) CN108175749B (enExample)
AR (2) AR083656A1 (enExample)
AU (1) AU2011361704B2 (enExample)
BR (1) BR112013010524A8 (enExample)
CA (1) CA2813985C (enExample)
CL (1) CL2013001120A1 (enExample)
CO (1) CO6781472A2 (enExample)
CR (2) CR20180289A (enExample)
CY (1) CY1119993T1 (enExample)
DK (1) DK2613769T3 (enExample)
DO (2) DOP2013000092A (enExample)
EC (2) ECSP13012647A (enExample)
ES (1) ES2647583T3 (enExample)
GT (1) GT201300102A (enExample)
HK (1) HK1243761A1 (enExample)
HR (1) HRP20171884T1 (enExample)
HU (1) HUE035169T2 (enExample)
IL (2) IL226215A (enExample)
LT (1) LT2613769T (enExample)
ME (1) ME02942B (enExample)
MX (2) MX345603B (enExample)
MY (1) MY189224A (enExample)
NO (1) NO2613769T3 (enExample)
NZ (1) NZ608907A (enExample)
PE (2) PE20171242A1 (enExample)
PH (1) PH12013500686A1 (enExample)
PL (1) PL2613769T3 (enExample)
PT (1) PT2613769T (enExample)
RS (1) RS56718B1 (enExample)
RU (2) RU2577859C2 (enExample)
SG (2) SG189477A1 (enExample)
SI (1) SI2613769T1 (enExample)
TW (2) TWI535699B (enExample)
UA (1) UA113500C2 (enExample)
UY (3) UY33692A (enExample)
WO (1) WO2012121758A1 (enExample)
ZA (2) ZA201302669B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
MX349533B (es) 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AR083946A1 (es) 2010-11-23 2013-04-10 Abbott Lab Metodos de tratamiento con inhibidores selectivos de bcl-2
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
AU2012352177A1 (en) 2011-12-13 2014-07-10 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
RU2648476C2 (ru) 2012-09-07 2018-03-26 Дженентек, Инк. Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2
EP2900219B1 (en) * 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
CA3090936C (en) 2013-03-13 2023-02-07 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US9006438B2 (en) 2013-03-13 2015-04-14 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
BR112016017564A8 (pt) 2014-01-28 2018-04-17 Buck Inst Res Aging métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
MX383378B (es) * 2014-02-05 2025-03-13 Merck Sharp & Dohme Llc Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina.
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
TW201618772A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
CN106793821B (zh) * 2014-08-29 2021-05-07 花王株式会社 含有难溶性多酚类的固体分散体的制造方法
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP6724136B2 (ja) 2015-11-03 2020-07-15 ジェネンテック， インコーポレイテッド がん治療のためのＢｃｌ−２阻害剤及びＭＥＫ阻害剤の組み合わせ
CN106957315B (zh) * 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
RU2018146513A (ru) * 2016-06-09 2020-07-09 Др. Редди'С Лабораторис Лимитед Твердые формы венетоклакса и способы получения венетоклакса
WO2018009444A1 (en) * 2016-07-06 2018-01-11 Concert Pharmaceuticals, Inc. Deuterated venetoclax
CN107648185A (zh) * 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US10800777B2 (en) 2016-10-14 2020-10-13 Mylan Laboratories Limited Polymorphic forms of VENCLEXTA
EP3333167A1 (en) * 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
US11053239B2 (en) * 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
AU2018255621B2 (en) 2017-04-18 2022-03-10 Fochon Pharmaceuticals, Ltd. Apoptosis-inducing agents
ES2948287T3 (es) 2017-08-23 2023-09-07 Guangzhou Lupeng Pharmaceutical Company Ltd Derivados heterocíclicos condensados como inhibidores de Bcl-2 para el tratamiento de enfermedades neoplásicas
WO2019135253A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Polymorphic forms of venetoclax
KR20200108298A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
AU2020349041A1 (en) 2019-09-18 2022-04-28 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic Bcl-2 family protein
CA3173041A1 (en) * 2020-02-24 2021-09-02 Guangzhou Lupeng Pharmaceutical Company Ltd. Hot melt extruded solid dispersions containing a bcl2 inhibitor
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
EP4656186A1 (en) * 2023-03-10 2025-12-03 ST Pharm Co., Ltd. Novel solid dispersion and method for preparing same

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5707648A (en) 1993-11-17 1998-01-13 Lds Technologies, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
TR200100149T2 (tr) 1998-07-06 2001-10-22 Bristol-Myers Squibb Company Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1217936C (zh) 1999-12-28 2005-09-07 卫材株式会社 含有磺酰胺的杂环化合物
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
NZ526531A (en) 2001-01-31 2005-02-25 Pfizer Prod Inc Ether derivatives useful as inhibitors of phosphodiesterase type IV (PDE4) isozymes
US6927009B2 (en) 2001-05-22 2005-08-09 Fuji Photo Film Co., Ltd. Positive photosensitive composition
AU2002259204B2 (en) 2001-06-06 2008-01-17 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP4598399B2 (ja) 2002-02-04 2010-12-15 エラン ファーマ インターナショナル，リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
DK1480679T3 (da) 2002-02-26 2007-09-03 Astrazeneca Ab Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
KR20040086452A (ko) 2002-02-26 2004-10-08 아스트라제네카 아베 항암 화합물 ｚｄ1839의 신규한 결정질 형태
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
TWI262077B (en) 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
WO2005105039A1 (en) 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ATE395905T1 (de) 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
CA2608333A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007043057A2 (en) 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US7151188B1 (en) 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
JP2009537535A (ja) 2006-05-15 2009-10-29 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
ES2360741T3 (es) 2006-07-14 2011-06-08 Chemocentryx, Inc. Triazolil fenil bencenosulfonamidas.
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
AU2007316558A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP5130305B2 (ja) 2007-02-15 2013-01-30 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしての２−アミノオキサゾリン
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
JP2010540634A (ja) 2007-10-01 2010-12-24 ザ・ジョンズ・ホプキンス・ユニバーシティー シクロホスファミドを用いて自己免疫神経疾患を処置する方法
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009064938A1 (en) 2007-11-16 2009-05-22 Abbott Laboratories Method of treating arthritis
JP2011506338A (ja) 2007-12-06 2011-03-03 アボット・ラボラトリーズ 癌の治療のためのａｂｔ−２６３の経口用組成物
BRPI0906490A2 (pt) 2008-01-15 2015-07-14 Abbott Lab Vetores de expressão de mamífero melhorados e uso dos mesmos
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
CN101548960B (zh) 2008-04-01 2012-11-07 沈阳药科大学 高溶出度口服联苯双酯胶囊及其制备方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CN106008322B (zh) * 2008-12-05 2018-09-04 Abbvie 公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US8959548B2 (en) * 2008-12-22 2015-02-17 Verizon Patent And Licensing Inc. Presenting advertisements with video program descriptions
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
BRPI1006116A2 (pt) * 2009-01-19 2018-03-13 Abbott Lab "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes".
BRPI1006115A8 (pt) 2009-01-19 2017-09-26 Abbott Lab "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
CN102448959B (zh) * 2009-05-26 2015-06-17 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
JP2012530704A (ja) 2009-06-18 2012-12-06 アボット・ラボラトリーズ 安定なナノ粒子状薬物懸濁液
BR112012006252A2 (pt) 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
MX349533B (es) 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
AR083946A1 (es) 2010-11-23 2013-04-10 Abbott Lab Metodos de tratamiento con inhibidores selectivos de bcl-2
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
JP6095678B2 (ja) 2011-11-11 2017-03-15 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 薬剤パッケージ用の不動態化、ｐＨ保護又は滑性皮膜、被覆プロセス及び装置

Also Published As

Publication number Publication date
CN103282025A (zh) 2013-09-04
CN108175749A (zh) 2018-06-19
KR20140052921A (ko) 2014-05-07
AU2011361704A1 (en) 2013-05-02
PE20140381A1 (es) 2014-04-21
UY33692A (es) 2012-04-30
IL251877B (en) 2019-03-31
KR101957137B1 (ko) 2019-03-13
NZ608907A (en) 2015-05-29
CA2813985C (en) 2019-01-15
AR083656A1 (es) 2013-03-13
EP2613769A1 (en) 2013-07-17
PL2613769T3 (pl) 2018-04-30
PE20171242A1 (es) 2017-08-24
ZA201302669B (en) 2014-10-29
JP6153638B2 (ja) 2017-06-28
CN108175749B (zh) 2021-09-10
CL2013001120A1 (es) 2013-10-04
HUE035169T2 (en) 2018-05-02
HRP20171884T1 (hr) 2018-01-12
UY37326A (es) 2019-02-28
DOP2017000003A (es) 2017-04-16
RS56718B1 (sr) 2018-03-30
ECSP22086925A (es) 2023-01-31
SG2014015077A (en) 2014-04-28
US20120108590A1 (en) 2012-05-03
LT2613769T (lt) 2018-02-12
MX2013004843A (es) 2013-10-01
PH12013500686A1 (en) 2013-05-27
CR20130224A (es) 2013-06-12
CO6781472A2 (es) 2013-10-31
RU2013124823A (ru) 2014-12-10
DOP2013000092A (es) 2013-09-30
ES2647583T3 (es) 2017-12-22
AU2011361704B2 (en) 2015-10-01
TW201636324A (zh) 2016-10-16
AR122475A2 (es) 2022-09-14
MX362113B (es) 2019-01-07
EP3219308A1 (en) 2017-09-20
TWI648261B (zh) 2019-01-21
SI2613769T1 (en) 2018-02-28
RU2633353C1 (ru) 2017-10-12
EP4218731A3 (en) 2023-08-16
EP4218731A2 (en) 2023-08-02
CN103282025B (zh) 2018-01-02
PT2613769T (pt) 2018-01-04
US20150148331A1 (en) 2015-05-28
JP2013544804A (ja) 2013-12-19
IL226215A (en) 2017-05-29
IL226215A0 (en) 2013-07-31
KR101836820B1 (ko) 2018-03-09
ME02942B (me) 2018-04-20
TWI535699B (zh) 2016-06-01
SG189477A1 (en) 2013-05-31
JP5902187B2 (ja) 2016-04-13
US11369599B2 (en) 2022-06-28
JP2016147878A (ja) 2016-08-18
GT201300102A (es) 2014-05-20
MY189224A (en) 2022-01-31
TW201242946A (en) 2012-11-01
WO2012121758A1 (en) 2012-09-13
HK1243761A1 (en) 2018-07-20
ECSP13012647A (es) 2013-07-31
IL251877A0 (en) 2017-06-29
BR112013010524A2 (pt) 2016-08-02
EP2613769B1 (en) 2017-09-27
BR112013010524A8 (pt) 2018-02-06
CR20180289A (es) 2018-06-26
KR20180024025A (ko) 2018-03-07
NO2613769T3 (enExample) 2018-02-24
ZA201401440B (en) 2015-06-24
DK2613769T3 (en) 2018-01-08
CA2813985A1 (en) 2012-09-13
UA113500C2 (xx) 2017-02-10
UY39192A (es) 2021-06-30
MX345603B (es) 2017-02-03
RU2577859C2 (ru) 2016-03-20

Similar Documents

Publication Publication Date Title
CY1119993T1 (el) Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης
CY1122218T1 (el) Αλατα και πολυμορφα της 8-φθορο-2-{4-[(μεθυλαμινο)μεθυλο]φαινυλο}-1,3,4,5-τετραϋδρο-6η-αζεπινο[5,4,3-cd]ινδολο-6-ονης
MX349533B (es) Dispersiones solidas que contienen un agente inductor de apoptosis.
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
TW200637614A (en) Bendamustine pharmaceutical compositions
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
BRPI1012959A8 (pt) Dispersoes solidas contendo um agente promotor de apoptose
MX2011011525A (es) Formulacion lipida estabilizada de promotor de apoptosis.
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
EA201490032A1 (ru) Лиофилизированные препараты fgf-18
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
MX2015006862A (es) Vacuna para enfermedad intrauterina.
CL2008001325A1 (es) Compuestos derivados de pirazol-piridinona; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar inflamacion, enfermedad de paget, osteoartritis, alzheimer, entre otras enfermedades.